Aim: To examine whether liquiritigenin, a newly found agonist of selective estrogen receptor-β, has neuroprotective activity against β-amyloid peptide (Aβ) in rat hippocampal neurons. Methods: Primary cultures of rat hippocampal neurons were pretreated with liquiritigenin (0.02, 0.2, and 2 μmol/L) prior to Aβ 25-35 exposure. Following treatment, viability of the cells was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide analysis and by a lactate dehydrogenase activity-based cytotoxicity assay. Intracellular Ca 2+ concentration ([Ca 2+ ] i ) and levels of reactive oxygen species (ROS), as well as apoptotic rates, were determined. Our studies were extended in tests of whether liquiritigenin treatment could inhibit the secretion of Aβ 1-40 as measured using an ELISA method. In order to analyze which genes may be involved, we used a microarray assay to compare gene expression patterns. Finally, the levels of specific proteins related to neurotrophy and neurodenegeration were detected by Western blotting. Results: Pretreated neurons with liquiritigenin in the presence of Aβ 25-35 increased cell viability in a concentration-dependent manner. Liquiritigenin treatment also attenuated Aβ 25-35 -induced increases in [Ca 2+ ] i and ROS level and decreased the apoptotic rate of neurons. Some genes, including B-cell lymphoma/leukemia-2 (Bcl-2), neurotrophin 3 (Ntf-3) and amyloid β (A4) precursor protein-binding, family B, member 1 (Apbb-1) were regulated by liquiritigenin; similar results were shown at the protein level by Western blotting. Conclusion: Our results demonstrate that liquiritigenin exhibits neuroprotective effects against Aβ 25-35 -induced neurotoxicity and that it can decrease the secretion of Aβ 1-40 . Therefore, liquiritigenin may be useful for further study as a prodrug for treatment of Alzheimer's disease.
Introduction
In addition to its classic function as a sex hormone, estrogen plays key regulatory roles in various biological pathways. It has outstanding neuroprotective and neurotrophic activities and has been linked to neurodegenerative diseases, including Alzheimer's disease (AD) [1, 2] . A large body of work has shown that estrogen can block β-amyloid peptide (Aβ)-induced neuronal cell death and influence Aβ secretion [3] [4] [5] [6] [7] . However, long-term compliance with estrogen administration is estimated to be no more than 15%-40% because of undesirable side effects [8] [9] [10] . As a result, several phytoestrogens with fewer side effects and potential neuroprotective effects have been developed as alternative treatment strategies [11, 12] . Liquiritigenin (7, 4 '-dihydroxyflavanone, Figure 1 ) is a flavonoid extracted from Glycyrrhizae radix that exhibits lifeenhancing properties and is frequently used in traditional Oriental medicine to treat injury or swelling and for detoxification. Our interest in liquiritigenin developed as a result of the following observations. First, liquiritigenin was shown to be a highly selective agonist of estrogen receptor-β (ERβ) [13] , an observation that is consistent with our previous findings (unpublished data). ERβ is expressed in brain centers related to learning and memory and is less likely than ERα to be related to sexual function [14, 15] . Second, liquiritigenin has been shown in several studies to exert cytoprotective effects [16, 17] ; recent studies demonstrate that liquiritigenin exerts anti-inflammatory effects through the NF-κB pathway [18] . Third, we previously observed that liquiritigenin did not induce proliferation of MCF-7 and T47D breast cancer cells (data not shown), which is consistent with other studies [13] . Finally, pharmacokinetic studies from our laboratory have demonstrated that liquiritigenin exhibits good intestinal absorption and blood-brain barrier permeability [19] . These characteristics suggest that liquiritigenin may have a therapeutic function in the brain.
Materials and methods

Cell culture
Primary rat hippocampal neurons were obtained from newborn Wistar rats (postnatal day 0, obtained from the Academy of Military Medical Science, grade SPF, certificate number: SCXK(Jing)2005-0013) as previously described [12] with minor modifications. Procedures were carried out in accordance with the Institutional Animal Care Guidelines of the Chinese Society of Laboratory Animals Science. Briefly, after being dissected from the brains of the rats, hippocampi were treated with 0.25% trypsin for no more than 30 min at 37 °C and were dissociated by repeated passage through a series of fire-polished, constricted Pasteur pipettes. Neurons were seeded into poly-L-lysine (100 μg/mL)-coated plates and grown in serumfree DMEM-F12 medium supplemented with 2% B27 (Sigma, USA). This method yielded cell cultures consisting of more than 90% neurons. Cell cultures were routinely observed by phase-contrast inverted microscopy and were maintained for 7 d before treatment.
Aβ is a 39−43 amino acid peptide that is derived from amyloid precursor protein. The toxicity of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is very similar to that of Aβ . Both peptides are easily amyloidogenic, so Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was used in the present study. Seven-day-old neurons were pretreated with or without 0.02, 0.2, or 2 μmol/L liquiritigenin (synthesized in our institute; purity >95% by HPLC) alone for 24 h; then 10 μmol/L Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Sigma, USA), the concentration of which was chosen as previously described [20] , was added together with the liquiritigenin for 72 h. To produce neurotoxicity, Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (diluted in saline) was incubated at 37 °C for 7 d to make fibril formation before use.
Cell viability detection
Seven-day-old neurons were plated into 96-well plates (5×10 4 cells/well) and treated with liquiritigenin for 24 h and Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] for 72 h. Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as previously described [21] . Absorbance at 540 nm was measured using a microplate reader (ThermoLab, USA). The viability of vehicle-treated control groups (not exposed to Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) was defined as 100%.
Lactate dehydrogenase activity-based cytotoxicity assay Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme expressed in most cells, including neurons. When the plasma membrane is damaged, LDH is rapidly released into the cell culture supernatant. In the context of this study, we used LDH release as a biochemical index of cytotoxicity. Culture supernatant 100 μL was collected and LDH activity was measured using LDH detection kits (BIOSINO, China) according to the manufacturer's instructions. Colorimetric absorbance at 570 nm was measured using an automatic chemistry analyzer (ELx800, Italy). LDH activity in each group was calculated as percentage of the LDH activity of cells that had been exposed to Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] alone, which was defined as 100%. ] i ) was determined using the Ca 2+ -sensitive fluorochrome Fluo-3/acetoxymethyl ester (Fluo-3/AM, Biotium, USA). Fluorescence intensity was analyzed using a fluorescence spectrophotometer (FOLARstar, BMGLABTech, German) with excitation and emission wavelengths of 488 nm and 526 nm; [Ca 2+ ] i was calculated according to the described method [22] .
Measurement of intracellular
Measurement of intracellular reactive oxygen species
The level of intracellular reactive oxygen species (ROS) was determined using 2,7-dichlorodihydro fluorescent diacetate (DCFH-DA, Beyotime, China), following the manufacturer's instructions. The fluorescence intensity of cells was measured with a fluorescence spectrophotometer, with excitation and emission wavelengths of 490 nm and 520 nm, respectively.
Hoechst 33342 staining
The morphology of nuclear chromatin was assessed by staining with the fluorescent dye Hoechst 33342 as described [11] . Briefly, cells were fixed with 3.7% paraformaldehyde (v/v) and then stained with Hoechst 33342 (10 μg/mL) for 10 min at room temperature. After washing, each field of cells was analyzed using a fluorescence microscope (Zeiss, Germany) and recordings were made using a CCD camera (Apogee). DNAfragmented cells stained with Hoechst 33342 take on a bright blue.
Flow cytometric detection of apoptotic cells
For detection of apoptotic rate, Annxin V-FITC/PI (Jingmei Biotech, China) staining was performed following the manufacturer's instructions. Cells that could be stained with Annxin V but not with PI were defined as apoptotic. Apoptotic rate was measured with a flow cytometer (FCM, Becton Dickinson, USA) using CellQuest software.
Treatment of cells with liquiritigenin to detect soluble Aβ 1-40
Seven-day-old neurons were cultured in 96-well dishes and treated separately in the presence of 0.02, 0.2, 2 μmol/L liquiritigenin or vehicle for 24 h. For each treatment, three wells containing the same number of cells were used. The levels of soluble Aβ (the predominant form of Aβ peptide) in the conditioned medium were assayed using the sensitive sandwich ELISA detection kit, following the manufacturer's instructions (Uscnlife, USA). Levels of Aβ 1-40 were expressed in pg/mL as deduced from the appropriate standard curve 
Microarray assay
In order to understand which genes may be influenced by exposure of neurons to liquiritigenin, a microarray technique was used to explore gene expression profiles. Seven-day-old cells were seeded into 6-well plates at a density of 2×10
6 /well and were treated with/without 2 μmol/L liquiritigenin for 24 h. The Oligo GEArray Rat Neurogenesis and Neural Stem Cell Microarray (ORN-404, Superarray, USA), which includes 263 genes, was chosen because it contains genes related to both neurotrophy and neuroprotection. After treatment, cells were lysed using 1 mL TRIzol (Sigma, USA) and immediately delivered to the manufacturer. The entire microarray procedure, including RNA preparation and reverse transcription PCR, was performed by the manufacturer. The fold change was calculated for each gene as the ratio of liquiritigenin/control. In this experiment, only the high dose of 2 μmol/L liquiritigenin was chosen and the assay was not repeated because of its costliness.
Western blotting
In light of results from microarray and similar studies [23] [24] [25] , we selected four representative proteins, including B-cell lymphoma/leukemia-2 (Bcl-2), Bcl-2-associated X protein (Bax), neurotrophin 3 (Ntf-3) and amyloid β (A4) precursor proteinbinding, family B, member 1 (Apbb-1), for further analysis to validate whether liquiritigenin affects related protein expression. For detection of Bcl-2, Bax and Ntf-3, seven-day-old rat hippocampal neurons were seeded into 6-well plates at a density of 2×10 6 cells/well. After an overnight incubation, cells were treated with/without liquiritigenin (0.02, 0.2, or 2 μmol/L) for 24 h, followed by addition of 10 μmol/L Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and further incubation with liquiritigenin for 72 h. For targeted detection of Apbb-1, cells were treated with liquiritigenin (0.02, 0.2, or 2 μmol/L) alone for 24 h, then lysed with 4 °C cell lysis buffer (Beyotime, China) as recommended by the manufacturer. SDS-PAGE and Western blotting were performed according to standard protocols [22] using 40 μg protein per lane. Primary antibodies were as follows: Bcl-2 (Beyotime, China, 1:500 dilution), Bax (Beyotime, China, 1:500 dilution), Ntf-3 (Chemicon, USA, 1:1000 dilution), Apbb-1 (Bioss, China, 1:200 dilution), β-tubulin (Walterson, China, 1:1000 dilution, as internal control) and secondary antibody (goat anti-rabbit or goat anti-mouse IgG-HRP, Zhongshan, China, 1:2000 dilution).
The grey levels were presented as the ratio against β-tubulin and were analyzed using the software Scion Image for Windows (http:// www.scioncorp.com).
Statistical analysis
All data, except those of microarray assay, are expressed as mean±SEM; assays were repeated in at least three independent experiments (in the context, "n" represents the number of repetitions), each performed in triplicate. Data comparisons among groups were assessed by one-way ANOVA. Between two groups, Dunnett's test was used; P<0.05 was assumed to indicate statistical significance.
Results
Liquiritigenin protects primary rat hippocampal neurons against Aβ 25-35 -induced cytotoxicity As shown in Figure 2A , Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Liquiritigenin protects neurons against Aβ 25-35 -induced apoptosis Nuclear morphology was evaluated using the membrane-permeable blue dye Hoechst 33342. As shown in Figure 3A , the content of DNA-fragmented cells increased after Aβ 25-35 treatment. There were fewer DNA-fragmented cells after incubation of the neurons with 0.2 or 2 μmol/L liquiritigenin.
Annexin V-FITC/PI staining gave similar results; Figure 3B shows typical histograms from FCM. As shown in Figure 3C , the apoptotic rate of cells treated with 10 μmol/L Aβ 25- 
Effects of liquiritigenin on some genes involved in neuro pro tection and neurotrophy
Using the rat neurogenesis and neural stem cell microarray assay, we could determine differential gene expression in liquiritigenin-treated and untreated cells through a simple side-by-side hybridization experiment. If the fold change is greater than 1, the result is reported as a fold up-regulation.
If the fold change is less than 1, the negative inverse of the result is reported as a fold down-regulation. Figure 5A shows the results of the microarray assay; from it, we can see that some genes were up-regulated whereas others were downregulated. Figure 5B shows quantitative analysis of the microarray assay, which indicating that the expression level of Bcl-2, the most important anti-apoptotic gene, was increased by 6.25-fold (n=1), while the expression level of Bax was similar to that of control (n=1). Ntf-3 and Ntf-5 were up-regulated by 7.65 and 5.43-fold, respectively (n=1). Furthermore, the expression of Apbb-1, which is related to amyloidosis, was sharply decreased by 13.2-fold (n=1) after liquiritigenin treatment.
Changes in related protein expression
The proteins Bcl-2, Bax, Ntf-3 and Apbb-1 were chosen for further analysis. Figure 5C shows a representative result of Western blotting. From the quantitative analysis ( Figure 5D In patients with AD, brain Aβ aggregates into clumps called oligomers that can accumulate and form deposits called amyloid plaques, which are thought to be a major pathologic mechanism of AD. Aβ-induced neurotoxicity has been attributed in various studies to Ca 2+ influx, generation of ROS, induction of apoptosis, and other causes. The present study confirms that Aβ 25-35 can cause neural cell death, an increase of Ca 2+ influx and generation of ROS, as previously evidenced in other studies [20] . In addition, we have shown that Aβ 25-35 treatment can decrease the expression of Ntf-3 protein, an important neurotrophic factor; such a decrease in Ntf-3 protein may also contribute to the neuronal death induced by Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] .
The present study provides evidence that liquiritigenin at a dosage in the range of 0.2-2 μmol/L can prevent Aβ 25-35 -induced injury to rat hippocampal neurons, as shown by cell viability measurements using MTT and LDH detection assays. In a previous study, Kim et al showed that liquiritigenin exerted anti-inflammatory effects against lipopolysaccharide in Raw264.7 cells at a concentration ranging from 3 to 30 μmol/L [18] . We reckon that the differences in effective dose observed in the two studies may be due to the use of different cells and/or different toxic factors.
It has been reported that ROS generation is a consequence of Ca 2+ accumulation [26] . However, in many experiments, free radicals are responsible for the increase in [Ca 2+ ] i . ROSinduced membrane damage causes further Ca 2+ influx, and resultant accentuated Ca 2+ influx will in turn induce the generation of further ROS [27] . In the present study, Aβ 25-35 elicited significant [Ca 2+ ] i increase and ROS accumulation, both of which contributed to the excitatory neurotoxicity of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , as previously reported [20] . Both [Ca
2+
] i increase and ROS accu- In the present study, cultured hippocampal neurons exposed to Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] for more than 72 h showed increased chromatin condensation, a typical feature of apoptotic cell death. Bcl-2 family proteins are a critical regulatory factor in cellular response to apoptosis through mitochondrial pathways. In most instances, anti-apoptotic and pro-apoptotic factors in the Bcl-2 family have synergistic effects and play alternating roles. In the present study, it was shown that liquiritigenin exerted its anti-apoptotic role in the presence of Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] at least in part through increasing the expression of Bcl-2, suggesting that liquiritigeinin could regulate mitochondrial function and thereby inhibit neuronal apoptosis. With regard to the underlying cellular mechanism, we previously observed that an ER antagonist, ICI 182 780, could partially block the anti-apoptotic effect of liquiritigenin in our culture system (unpublished data). Since liquiritigenin has a 20-fold higher affinity for ERβ than for ERα [13] , it is likely that its neuroprotective ability is mediated by ERβ. Meanwhile, the partial blocking effect of ICI 182 780 also suggests that the protective effect may be mediated by multiple pathways, including that of mitogenactivated protein kinase (MAPK) [3] . The results of the microarray assay and Western blotting in the present study indicate that liquiritigenin probably has some neurotrophic actions, including causing an increase in the expression of Ntf-3 at both the genetic and protein levels. Since we observed that Aβ 25-35 treatment inhibited the expression of Ntf-3, whereas liquiritigenin treatment could attenuate this effect, the action of liquiritigenin on Ntf-3 may account to some extent for its neuroprotective effect. This deduction is consistent with previous findings showing that Ntf-3 protects primary cortical [28] . Targeting generation and initial formation of amyloid assemblies is a preferred approach for therapeutic intervention in amyloidosis, and studies have reported that estrogen could be used for this purpose [4, 6, 7] . Most Aβ is composed of a peptide designated Aβ 40 , Aβ 1-40 , or, in some cases, Aβ x-40 . Because Aβ 1-40 is a main form of Aβ, our demonstration that liquiritigenin inhibits its secretion is meaningful. The sensitive sandwich ELISA was used in this experiment because the expression level of Aβ 1-40 was so low that it could not be detected using Western blotting or other methods. Herein, we have also shown that Apbb-1, a peptide that forms the extracellular amyloid fibrils of Alzheimer senile plaques, was down-regulated by liquiritigenin. This finding could explain why liquiritigenin inhibited the accumulation of Aβ, but more research is needed to verify this hypothesis.
In pioneer studies in the field of AD treatment using SERMs, Carroll et al found that both PPT (a selective ERα agonist) and DPN (a selective ERβ agonist) could reduce Aβ accumulation in the brain in 3×Tg-AD mice [29] . The present research reports that a newly found ERβ agonist, liquiritigenin, showed satisfactory effects against Aβ 25-35 -induced insults in primary neurons. Liquiritigenin may therefore serve as a named NeuroSERM [30, 31] , in other words, an estrogen alternative that selectively targets and activates estrogen mechanisms of action in the brain while avoiding activation of estrogen receptors peripheral to the brain, particularly in reproductive organs. Furthermore, our results are consistent with the finding that the expression of the ERβ gene is positively correlated with increased levels of learning and memory ability in some mouse models of AD, while ERα shows almost no relationship to learning and memory improvements [32] . Our data confirm the potential of NeuroSERMs in protecting against AD neuropathology and support continued development and investigation in this field. An important qualification is that we have examined the effects of liquiritigenin only in vitro; follow-up studies that address the application of liquiritigenin in vivo and its potential therapeutic value are needed. From a signaling standpoint, there is a significant need for targeted research to better elucidate the genomic/ non-genomic signaling pathways through which liquiritigenin exerts its effects. Future research should be aimed at rapidly providing answers to these key questions.
